X0508 4 2024-06-11 true 0001654151 Deciphera Pharmaceuticals, Inc. NA 0001410514 Kelly Thomas Patrick C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 false true false false Chief Financial Officer false Common Stock 2024-06-11 4 A false 34157 A 114507 D Common Stock 2024-06-11 4 D false 72029 D 42478 D Common Stock 2024-06-11 4 U false 42478 D 0 D Stock Option (Right to Buy) 1.89 2024-06-11 4 D false 85456 D Common Stock 85456 0 D Stock Option (Right to Buy) 3.95 2024-06-11 4 D false 5650 D Common Stock 5650 0 D Stock Option (Right to Buy) 6.13 2024-06-11 4 D false 103219 D Common Stock 103219 0 D Stock Option (Right to Buy) 9.23 2024-06-11 4 D false 82265 D Common Stock 82265 0 D Stock Option (Right to Buy) 8.27 2024-06-11 4 D false 82000 D Common Stock 82000 0 D Stock Option (Right to Buy) 15.48 2024-06-11 4 D false 65900 D Common Stock 65900 0 D Stock Option (Right to Buy) 15.92 2024-06-11 4 D false 69100 D Common Stock 69100 0 D Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. /s/ Jeffrey M. Held, Attorney-in-Fact 2024-06-11